ArticleOncotarget2017
Circulating miRNAs as novel diagnostic biomarkers in hepatocellular carcinoma detection: a meta-analysis based on 24 articles.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A comprehensive evaluation of full-spectrum cell-free RNAs highlights cell-free RNA fragments for early-stage hepatocellular carcinoma detection.EBioMedicine · 2023Pooled it
- Novel biomarkers for monitoring and management of hepatocellular carcinoma.Cancer cell international · 2024Review
- Novel insights into the impact of liver inflammatory responses on primary liver cancer development.Liver research (Beijing, China) · 2023Review
- Review
- Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?Journal of clinical medicine · 2020Review
- miR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2.Oncology research · 2020Article
- BiomarkersWorld journal of clinical cases · 2019Review
- Clinical value of miRNA-122 in the diagnosis and prognosis of various types of cancer.Oncology letters · 2019Article
- Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma.International journal of molecular sciences · 2019Article
- Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets.Seminars in liver disease · 2019Review
- Diagnostic Value of Circulating microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Journal of Cancer · 2019Article
- Identification of Platform-Independent Diagnostic Biomarker Panel for Hepatocellular Carcinoma Using Large-Scale Transcriptomics Data.Frontiers in genetics · 2019Article
- The Epigenetic Regulation of HCC Metastasis.International journal of molecular sciences · 2018Review
- MicroRNA199a-Based Post-transcriptional Detargeting of Gene Vectors for Hepatocellular Carcinoma.Molecular therapy. Nucleic acids · 2018Article
- Prognostic role of miR-760 in hepatocellular carcinoma.Oncology letters · 2018Article
- Liquid biopsies for hepatocellular carcinoma.Translational research : the journal of laboratory and clinical medicine · 2018Review
- Synergistic and independent action of endogenous microRNAs 122a and 199a for post-transcriptional liver detargeting of gene vectors.Scientific reports · 2018Article
- Expression Analysis of Serum microRNA-34a and microRNA-183 in Hepatocellular CarcinomaAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Role of microRNAs in the main molecular pathways of hepatocellular carcinoma.World journal of gastroenterology · 2018Review
- Extensive screening of microRNA populations identifies hsa-miR-375 and hsa-miR-133a-3p as selective markers for human rectal and colon cancer.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnostic value and suitability of circulating miRNAs for the detection of hepatocellular carcinoma have been inconsistent in the literature. A meta-analysis is used to systematically evaluate the diagnostic value of circulating miRNAs. Eligible studies were selected and the heterogeneity was assessed by subgroup analysis, meta-regression, and publication bias. After strictly and comprehensive screening, the source methods, internal reference and the cut-off values of the included miRNAs were first listed. Circulating miRNAs demonstrated a relatively good diagnostic value in hepatocellular carcinoma, In the subgroup analysis, diagnosis odds ratio showed a higher accuracy with multiple miRNAs than with a single miRNA as well as with serum types than plasma types. In addition, although miRNAs have many expression patterns, the high frequency expression miRNAs (miR-21, miR-199 and miR-122) might be more specific for the diagnosis of hepatocellular carcinoma.The sources of heterogeneity might be related to the number of miRNAs and the specimen types in meta-regression. Furthermore, it's surprised that the pooled studies were first demonstrated publication bias (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.